{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chang TC"],"funding":["NCI NIH HHS","NIGMS NIH HHS"],"pagination":["e0226464"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7546483"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(10)"],"pubmed_abstract":["Metaplastic breast carcinoma (MBC) is a clinically aggressive and rare subtype of breast cancer, with similar features to basal-like breast cancers. Due to rapid growth rates and characteristic heterogeneity, MBC is often unresponsive to standard chemotherapies; and novel targeted therapeutic discovery is urgently needed. Histone deacetylase inhibitors (DACi) suppress tumor growth and metastasis through regulation of the epithelial-to-mesenchymal transition axis in various cancers, including basal-like breast cancers. We utilized a new MBC patient-derived xenograft (PDX) to examine the effect of DACi therapy on MBC. Cell morphology, cell cycle-associated gene expressions, transwell migration, and metastasis were evaluated in patient-derived cells and tumors after treatment with romidepsin "],"journal":["PloS one"],"pubmed_title":["Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor."],"pmcid":["PMC7546483"],"funding_grant_id":["R01 CA174785","R15 CA176496","U54 GM104940","R01 CA125806"],"pubmed_authors":["Chang TC","Miele L","Matossian MD","Bunnell BA","Elliott S","Riker AI","Burow ME","Burks HE","Del Valle L","Ucar DA","Martin E","Wathieu H","Zabaleta J","Gill S","Sabol RA","Collins-Burow BM"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.","description":"Metaplastic breast carcinoma (MBC) is a clinically aggressive and rare subtype of breast cancer, with similar features to basal-like breast cancers. Due to rapid growth rates and characteristic heterogeneity, MBC is often unresponsive to standard chemotherapies; and novel targeted therapeutic discovery is urgently needed. Histone deacetylase inhibitors (DACi) suppress tumor growth and metastasis through regulation of the epithelial-to-mesenchymal transition axis in various cancers, including basal-like breast cancers. We utilized a new MBC patient-derived xenograft (PDX) to examine the effect of DACi therapy on MBC. Cell morphology, cell cycle-associated gene expressions, transwell migration, and metastasis were evaluated in patient-derived cells and tumors after treatment with romidepsin ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2025-04-19T23:38:34.817Z","creation":"2020-10-29T10:56:53Z"},"accession":"S-EPMC7546483","cross_references":{"pubmed":["33035223"],"doi":["10.1371/journal.pone.0226464"]}}